At 12 months , both bone-specific alkaline phosphatase and urinary N-telopeptide were significantly reduced , by 37.79 % ( d = -9.90 ; 1.92 SE ) and 27.21 % ( d = -11.68 ; 4.80 SE ) respectively , in the alendronate group ; in the control group , these levels increased ( P < 0.001 ) .